FDA pick faces questioning on ties to industry he'd regulate

April 05, 2017 - 4:05 am

WASHINGTON (AP) — President Donald Trump's nominee to head the Food and Drug Administration goes before a Senate committee to answer questions about his extensive financial ties to medical companies he could wind up regulating.

Dr. Scott Gottlieb is a physician-turned-health consultant who's criticized what he calls unnecessary FDA regulations. But he has generally supported the agency's mission of ensuring that prescription drugs and medical devices are safe and effective.

Gottlieb was a deputy FDA commissioner under President George W. Bush.

Critics have focused on Gottlieb's financial entanglements, citing government data showing he received hundreds of thousands of dollars in consulting or other fees from several FDA-regulated companies in recent years.

In ethics documents, Gottlieb says that if confirmed he would recuse himself for a year from decisions involving about 20 health-related companies.

AP Editorial Categories: 
Comments ()